TandemAI has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors. Since its founding in October 2021, the company has raised over $80M. With a team of more than 300 professionals, TandemAI’s AI-powered, fully integrated drug discovery engine has delivered over ten candidates that are now in—or soon to enter—clinic...